Prostate Cancer Recurrence After Surgery Linked to Pelvic Inflammation
A recent study is the first to examine the association between pelvic inflammation and prostate cancer biology and outcomes.
A recent study is the first to examine the association between pelvic inflammation and prostate cancer biology and outcomes.
68Ga-PSMA-11 PET scans have a 40% sensitivity for detecting pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer, data show.
Real-world data validate recently reported findings from clinical trials.
Patients who underwent ureteroscopic management of low-risk UTUC had a 5-year cancer-specific survival rate of 92.6%.
Overall and disease-free survival among patients undergoing surgical resection for MIUC is low despite increasing use of neoadjuvant chemotherapy.
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.
Findings from a new study can help individualize prognoses for men with biochemical recurrence of prostate cancer after radical prostatectomy.
Greater muscle mass independently predicts longer survival in men with metastatic or castration-resistant prostate cancer, a study found.